Dolutegravir/Lamivudine Just As Effective As Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate In Maintaining Viral Suppression Among People With HIV, Research Shows

MedPage Today (7/29, Kahn) reports, “The two-drug regimen dolutegravir/lamivudine (DTG/3TC; Dovato) was just as effective as the three-drug regimen bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF; Biktarvy) for maintaining viral suppression in people with HIV, according to the Spanish phase IV PASO-DOBLE trial.” At the 48 week mark, “2.2% of patients who switched from their previous antiretroviral therapy (ART) to a DTG/3TC regimen had a viral load of HIV-1 RNA ≥50 copies/mL versus 0.7% who switched to BIC/FTC/TAF, for a risk difference of 1.4% (95% CI -0.5 to 3.4).” The findings were presented at the International AIDS Conference in Munich.